← Leaderboards
Sung Won Choi
University Of Michigan At Ann Arbor
$6,756,881
Attributed
$7,449,469
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2011–25$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,149,559 · 8
AHRQ$299,910 · 1
By mechanism
R01$3,976,760 · 2
T32$903,359 · 1
K24$737,154 · 1
R21$670,748 · 2
K23$657,630 · 1
UG1$481,818 · 1
Top collaborators
- Jordan A Shavit2 shared
- Gregory Yanik2 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Scott Michael Schuetze$8,096,162
- Inbal Billie Nahum-Shani$11,421,341
- Craig J Galban$12,293,457
- Gregory Peter Kalemkerian$1,137,226
- Daniel R Wahl$6,515,358
Others in their field
Top investigators on “Skills”
- Christopher McKay · Battelle Memorial Institute$134,148,552
- Katherine M Thibault · Battelle Memorial Institute$134,148,552
- Albert F Suchy · Woods Hole Oceanographic Institution$115,771,203
- Stanley M Lemon · Univ Of North Carolina Chapel Hill$110,090,673
- Robert Stanley Sherwin · Yale University$96,841,314
- Lee Marshall Nadler · Dana-Farber Cancer Inst$89,956,287
Research focus
SkillsInsightHematological DiseaseClinical TrialsAcute Graft Versus Host DiseaseAllogenicPreventHistone Deacetylase InhibitorTransplant RecipientsFutureVorinostatGrantInnovationProphylactic TreatmentPrevention StrategyDesignHigh RiskResourcesPatient Self-ReportTrainingMultidisciplinaryMorbidity - Disease RateAreaFunding
Grant awards (30)
Boxer Training Program in Hematology$324,054
T32 · FY2025 · HL
BMT Core- University of Michigan Core Clinical Consortium for the BMT Clinical Trials Network (BMT CTN)$226,361
UG1 · FY2025 · HL
Patient-Oriented Research and Mentoring in Hematopoietic Cell Transplantation$123,253
K24 · FY2025 · HL · contact PI
Boxer Training Program in Hematology$579,305
T32 · FY2024 · HL
Phase I/II clinical trial of HDAC inhibition for GVHD prevention in children, adolescents, and young adults$422,892
R01 · FY2024 · CA · contact PI
BMT Core- University of Michigan Core Clinical Consortium for the BMT Clinical Trials Network (BMT CTN)$255,457
UG1 · FY2024 · HL
Patient-Oriented Research and Mentoring in Hematopoietic Cell Transplantation$123,253
K24 · FY2024 · HL · contact PI
Phase I/II clinical trial of HDAC inhibition for GVHD prevention in children, adolescents, and young adults$435,611
R01 · FY2023 · CA · contact PI
Roadmap 2.0: A randomized controlled trial using a technology-mediated platform in family caregivers of BMT patients$351,000
R01 · FY2023 · HL · contact PI
Patient-Oriented Research and Mentoring in Hematopoietic Cell Transplantation$123,253
K24 · FY2023 · HL · contact PI
Patient-Oriented Research and Mentoring in Hematopoietic Cell Transplantation$120,889
K24 · FY2023 · HL · contact PI
Chronic GVHD and Management of its Sequelae$22,000
R13 · FY2023 · HL · contact PI
Phase I/II clinical trial of HDAC inhibition for GVHD prevention in children, adolescents, and young adults$435,611
R01 · FY2022 · CA · contact PI
Roadmap 2.0: A randomized controlled trial using a technology-mediated platform in family caregivers of BMT patients$351,000
R01 · FY2022 · HL · contact PI
Patient-Oriented Research and Mentoring in Hematopoietic Cell Transplantation$123,253
K24 · FY2022 · HL · contact PI
Phase I/II clinical trial of HDAC inhibition for GVHD prevention in children, adolescents, and young adults$461,557
R01 · FY2021 · CA · contact PI
Roadmap 2.0: A randomized controlled trial using a technology-mediated platform in family caregivers of BMT patients$351,000
R01 · FY2021 · HL · contact PI
Patient-Oriented Research and Mentoring in Hematopoietic Cell Transplantation$123,253
K24 · FY2021 · HL · contact PI
Phase I/II clinical trial of HDAC inhibition for GVHD prevention in children, adolescents, and young adults$466,089
R01 · FY2020 · CA · contact PI
Roadmap 2.0: A randomized controlled trial using a technology-mediated platform in family caregivers of BMT patients$351,000
R01 · FY2020 · HL · contact PI
Roadmap 2.0: A randomized controlled trial using a technology-mediated platform in family caregivers of BMT patients$351,000
R01 · FY2019 · HL · contact PI
Vorinostat for GVHD prevention in unrelated donor myeloblative conditioning BMT$168,563
R21 · FY2016 · CA · contact PI
Vorinostat for GVHD prevention in unrelated donor myeloblative conditioning BMT$202,275
R21 · FY2015 · CA · contact PI
Personalized Engagement Tool for Pediatric BMT Patients and Caregivers$133,701
R21 · FY2015 · HS · contact PI
Phase II Trial of Vorinostat plus Tacrolimus and Mycophenolate to Prevent GVHD$132,300
K23 · FY2015 · AI · contact PI
Personalized Engagement Tool for Pediatric BMT Patients and Caregivers$166,209
R21 · FY2014 · HS · contact PI
Phase II Trial of Vorinostat plus Tacrolimus and Mycophenolate to Prevent GVHD$132,300
K23 · FY2014 · AI · contact PI
Phase II Trial of Vorinostat plus Tacrolimus and Mycophenolate to Prevent GVHD$130,940
K23 · FY2013 · AI · contact PI
Phase II Trial of Vorinostat plus Tacrolimus and Mycophenolate to Prevent GVHD$131,045
K23 · FY2012 · AI · contact PI
Phase II Trial of Vorinostat plus Tacrolimus and Mycophenolate to Prevent GVHD$131,045
K23 · FY2011 · AI · contact PI